Evidence map›Paper›PMID 33324416›Full record

ReviewFrontiers in immunology2020

Role of Vascular Smooth Muscle Cell Plasticity and Interactions in Vessel Wall Inflammation.

Vitaly Sorokin, Keeran Vickneson, Theo Kofidis, Chin Cheng Woo, Xiao Yun Lin, Roger Foo, Catherine M Shanahan

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 176 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
176citing papers in PubMed, 2 pooled it
11.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

176 citing papers in PubMed, 2 syntheses or guidelines pooled it, 272 citations in OpenAlex.

  1. Direct Vascular Effects of Angiotensin II (A Systematic Short Review).International journal of molecular sciences · 2024
    Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Review
  20. Review

116 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 2 countries.

Vitaly SorokinDepartment of Surgery, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
Keeran VicknesonSchool of Medicine, University of Dundee, Dundee, United Kingdom.
Theo KofidisDepartment of Surgery, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
Chin Cheng WooDepartment of Surgery, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
Xiao Yun LinDepartment of Cardiac, Thoracic and Vascular Surgery, National University Hospital, National University Health System, Singapore, Singapore.
Roger FooCardiovascular Research Institute, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
Catherine M ShanahanSchool of Cardiovascular Medicine and Sciences, James Black Centre, King's College London, London, United Kingdom.
National University Hospital · SGNational University of Singapore · SGAgency for Science, Technology and Research · SGKing's College London · GBUniversity of Dundee · GB

Funding

British Heart Foundation RG/17/2/32808
6 · The paper itself

Abstract

The pathobiology of atherosclerotic disease requires further elucidation to discover new approaches to address its high morbidity and mortality. To date, over 17 million cardiovascular-related deaths have been reported annually, despite a multitude of surgical and nonsurgical interventions and advances in medical therapy. Existing strategies to prevent disease progression mainly focus on management of risk factors, such as hypercholesterolemia. Even with optimum current medical therapy, recurrent cardiovascular events are not uncommon in patients with atherosclerosis, and their incidence can reach 10-15% per year. Although treatments targeting inflammation are under investigation and continue to evolve, clinical breakthroughs are possible only if we deepen our understanding of vessel wall pathobiology. Vascular smooth muscle cells (VSMCs) are one of the most abundant cells in vessel walls and have emerged as key players in disease progression. New technologies, including

Indexed as

AnimalsAtherosclerosisHumansInflammationMuscle, Smooth, VascularMyocytes, Smooth MuscleVasculitisatherosclerosisimmune-likeinflammationsmooth muscle cell phenotypevascular smooth muscle cells

Identifiers

PMID33324416
PMCPMC7726011
OpenAlexW3110282950

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.